Innovative drug infusion technology for laboratory animals.

Japanese English
resources e-book video slide qa
SMP-310R SMP-200 null null null null null null null null


  • News7 new publications: Four in Nature Aging (2023), Laboratory Investigation 103.1 (2023), Endocrinology 164.4 (2023) and Epilepsy Research (2023) respectively. 4 at preprint stage in bioRxiv (2023). See and for full details. Here are 2:-

    Moigneu, Carine, et al. "Systemic GDF11 attenuates depression-like phenotype in aged mice via stimulation of neuronal autophagy." Nature Aging (2023): 1-16. [Open Access]

    Hasegawa, Tomoka, et al. "Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats." Endocrinology 164.4 (2023): bqad022.[Open Access]

    March 3, 2023

  • NewsRecent user/customer feedback; " Thank your company for developing this miniaturized programmable pump that has really been a game changer in this work (and promise to be of tremendous help in the field of Neuroendocrinology, Endocrinology and Metabolism in the future) and enabled the completion of preclinical studies in mice that paved the way to human clinical trials. "

    September 9, 2022

  • NewsDiscovery and Characterization of JDQ443: a Structurally Novel Covalent Inhibitor of KRASG12C

    Elizabeth McKenna, PhD, interviews Saskia Brachmann, PhD, Anna Farago, MD, PhD, and Andreas Weiss, PhD, about their paper describing a novel KRAS G12C inhibitor that was published concurrently with a Clinical Trials Minisymposium presentation at the 2022 AACR Annual Meeting. iPRECIO SMP-310R Programmable pumps were used to better understand the relationship between PK, target occupancy, and efficacy.

    July 7, 2022

  • Event[Webinar] "Discovery of JDQ443, a structurally novel, potent and selective covalent oral inhibitor of KRASG12C"; MedChemCASES #16: Dr. Simona Cotesta - " We describe the hit to lead and lead optimization by structure-based design of the novel chemical series leading to the discovery of NVP-JDQ443 (JDQ443), a novel, potent and selective, orally bioavailable KRASG12C covalent inhibitor. JDQ443 showed dose dependent antitumor efficacy in KRAS G12C-mutated cell-derived models and is currently in clinical development as monotherapy as well as in combination with TNO155, a SHP2 inhibitor (NCT04699188). " excerpt from

    dr Simona Cotesta (Novartis)
    June 22, 2022
    5:00 PM (Berlin time)
    Registration link:

    June 17, 2022

  • NewsiPRECIO SMP-310R Programmable pumps were used to better understand the relationship between PK, target occupancy, and efficacy.
    " These findings demonstrate that antitumor activity can be achieved under both q.d. and b.i.d. dosing. To better understand the relationship between PK, target occupancy, and efficacy, a continuous infusion xenograft study was performed in the LU99 xenograft model and the PK/TO model applied to estimate the resulting levels of KRAS(G12C) target occupancy. " excerpt from publication, "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRAS(G12C) Wiess et al. Cancer Discov OF1–OF18. [Open Access]

    June 1, 2022

Our Mission with
iPRECIO® Product Portfolio:

Make it as easy as possible to evaluate efficacy of molecules/agents in different animal models and species.

Make the results as relevant as possible to the clinic. (Exposure profile, quantitative pharmacology, untethered free moving (stress free, group housing (socialization), ..…)

The use of iPRECIO® pumps will have a positive impact on experimental conditions and the relevance of results achieved. Initial costs maybe higher but in the long run the use of the pump could be cost saving in the context of the whole compound development.

insidescientific e-book insidescientific slide qanda

Page top

Privacy Policy